Infusion fluids contain harmful glucose degradation products
- First Online:
- Cite this article as:
- Bryland, A., Broman, M., Erixon, M. et al. Intensive Care Med (2010) 36: 1213. doi:10.1007/s00134-010-1873-x
- 476 Views
Glucose degradation products (GDPs) are precursors of advanced glycation end products (AGEs) that cause cellular damage and inflammation. We examined the content of GDPs in commercially available glucose-containing infusion fluids and investigated whether GDPs are found in patients’ blood.
The content of GDPs was examined in infusion fluids by high-performance liquid chromatography (HPLC) analysis. To investigate whether GDPs also are found in patients, we included 11 patients who received glucose fluids (standard group) during and after their surgery and 11 control patients receiving buffered saline (control group). Blood samples were analyzed for GDP content and carboxymethyllysine (CML), as a measure of AGE formation. The influence of heat-sterilized fluids on cell viability and cell function upon infection was investigated.
All investigated fluids contained high concentrations of GDPs, such as 3-deoxyglucosone (3-DG). Serum concentration of 3-DG increased rapidly by a factor of eight in patients receiving standard therapy. Serum CML levels increased significantly and showed linear correlation with the amount of infused 3-DG. There was no increase in serum 3-DG or CML concentrations in the control group. The concentration of GDPs in most of the tested fluids damaged neutrophils, reducing their cytokine secretion, and inhibited microbial killing.
These findings indicate that normal standard fluid therapy involves unwanted infusion of GDPs. Reduction of the content of GDPs in commonly used infusion fluids may improve cell function, and possibly also organ function, in intensive-care patients.
KeywordsGlucoseInfusion fluidsToxicityAdvanced glycation end productsNeutrophilsInnate defenseCell survival
Isotonic glucose solutions are frequently used in intensive care units (ICUs) to hydrate patients with acute disease or after surgery. These commercially available fluids contain between 2.5% and 50% glucose and are heat-sterilized to assure sterility of the products. Beyond hydration, these sterile products provide calories. Dysregulated glucose homeostasis occurs frequently in critically ill patients, but strict glycemic control does not decrease infectious morbidity, mortality, and length of stay in the ICU [1–4]. Glucose is seen as an inexpensive and secure source of energy on the one hand, and as a harmful substance on the other. What is perhaps less known is that the sterilization process of these fluid products leads to degradation of the glucose to highly bioreactive glucose degradation products (GDPs).
Glucose is used as an osmotic agent in fluids for peritoneal dialysis (PD) to remove water from patients with renal failure. Heat-sterilization of glucose-containing PD fluids promotes formation of a large number of GDPs . Several GDPs, such as 3-deoxyglucosone (3-DG), 3,4-dideoxyglucosone-3-ene (3,4-DGE), 5-hydroxymethyl-2-furaldehyde (5-HMF), and formaldehyde, have been identified in PD fluids [6, 7]. At the cellular level, aldehydes disrupt cell signaling and cause extensive damage to membrane lipids, cellular proteins, mitochondrial function, RNA, and DNA . The most bioreactive GDP in heat-sterilized PD solutions is 3,4-DGE . This toxic molecule was found to impair wound healing and to induce apoptosis in human leukocytes and renal epithelial cells [9–11]. Highly reactive GDPs, such as 3,4-DGE, react instantly with different molecules, while others, such as 3-DG and 5-HMF, remain in circulation .
After reaching the blood, GDPs bind to serum proteins, which gives rise to advanced glycation end products (AGE) . AGEs are known to be involved in oxidative stress and are associated with cardiovascular morbidity and renal injury [14–16]. By using new manufacturing techniques, PD solutions with low GDP content have been produced [17, 18]. Such low-GDP PD solutions have been shown to reduce serum AGE levels [13, 19] and decrease serum 3-DG concentrations . Several other clinical studies have demonstrated that removal of GDPs from fluids leads to decreased inflammation, preserved kidney function, and improved patient outcomes [19, 21–23].
In order to evaluate whether isotonic glucose-containing infusion fluids include toxic GDPs, we examined the content of such substances in commercially available glucose solutions and the effect they exhibited on neutrophil function. Furthermore, we analyzed patients’ blood for GDPs and CML after receiving standard glucose-containing fluid therapy in the postoperative setting and compared the serum levels with those of patients receiving buffered saline.
Content of GDPs in the investigated infusion fluids
GDP concentrations (μM)b (mean ± SEM)
Glucos Fresenius 200
Fresenius Kabi AB
583 ± 9.7
59 ± 1.2
105 ± 7.7
19 ± 3.4
Glucos Fresenius 300
Fresenius Kabi AB
790 ± 21.7
56 ± 2.3
146 ± 7.1
34 ± 4.7
Fresenius Kabi AB
141 ± 0.7
22 ± 1.1
2 ± 0.2
17 ± 0.7
Baxter Medical AB
400 ± 9.7
50 ± 0.1
42 ± 1.6
10 ± 3.0
Glucos Baxter 25/50
Baxter Medical AB
123 ± 0.8
22 ± 0.2
2 ± 0.1
10 ± 1.1
Baxter Medical AB
238 ± 3.9
35 ± 0.6
17 ± 0.4
4 ± 1.2
Glucos Baxter Na40 K20
Baxter Medical AB
358 ± 5.4
59 ± 0.4
10 ± 0.3
21 ± 2.8
1,374 ± 47.9
47 ± 2.7
2,463 ± 64.2
44 ± 5.1
The study was approved by the Regional Ethical Review Board (DNR 207/2007) of Lund University, Sweden. After patients gave written informed consent to be included in the study, 11 patients (6 women and 5 men) receiving glucose-containing postoperative infusion fluids were included in the standard group, and 11 patients (6 women and 5 men) receiving buffered saline (Ringer’s acetate) were included in the control group. Serum was analyzed for GDPs and CML.
Studies of effects of GDPs on cell viability and cell function
Cell viability was determined on isolated human neutrophils using the Thiazolyl blue tetrazolium bromide (MTT) assay. As an experimental infection model, neutrophils were infected with E. coli in the presence of GDPs or with infusion fluids 2 and 3 or their respective sterile filtered control fluids. Secretion of CXCL8 and interleukin 6 (IL-6) by the infected neutrophils was quantified in supernatants by enzyme-linked immunosorbent assay (ELISA, RD Systems Europe). Capacity of neutrophil microbial killing was measured by Fc-OxyBURST (Invitrogen) according to the manufacturer’s instructions.
Detailed methods are described in the Electronic Supplementary Material.
GDPs found in all investigated infusion fluids
In all of the tested fluids, 3-DG, 3,4-DGE, 5-HMF, and formaldehyde were found (Table 1). The concentration of 3-DG varied from 123 to 790 μM, of 3,4-DGE from 22 to 59 μM, of 5-HMF from 2 to 146 μM, and of formaldehyde from 4 to 34 μM (Table 1). The concentration of methylglyoxal was between 7 and 17 μM in fluids 3 and 5–7, but below the detection limit (1.0 μM) for the rest of the fluids. Acetaldehyde was only found in fluids 3, 5, and 7, at very low concentrations (1–2 μM) and close to the limit of detection (<1.1 μM). Glyoxal concentration was below the detection limit (3.4 μM) in most of the fluids, except fluid 3 that contained 31 μM. The concentrations of acetaldehyde, methylglyoxal, and glyoxal were far lower than the LC50 values [7, 24]. The concentrations of GDPs in sterile filtered control fluids were below the limit of detection.
GDPs in blood circulation
Serum concentrations (μM) of 3-DG in patients receiving the glucose-containing infusion fluids
Urinary GDP levels
Patients’ urine was collected throughout the study for analysis of GDPs. Urine concentrations were then compared with the amount of 3,4-DGE, 3-DG, and 5-HMF that the patient group received during their therapy (see Supplementary Fig. 1). An average patient in the standard group received approximately 1.7 l infusion fluids, which contained 47 mg 3-DG, 7 mg 3,4-DGE, 2 mg 5-HMF, and 0.4 mg formaldehyde. A tenth of the infused 3-DG was found in the urine (4.5 mg, P = 0.0002), while the amount of 5-HMF was four times higher (8.7 mg, P = 0.0314) than the infused amount. We found no 5-HMF in the control group and on average 0.1 mg 3-DG (P ≤ 0.001 compared with the patient group, data not shown). No 3,4-DGE or formaldehyde was found in urine.
Heat-sterilized infusion fluids reduce cell viability
Dose response and lethal concentrations
To investigate the influence of GDPs on human cells, neutrophils were incubated with different concentrations of 3,4-DGE, 3-DG, and 5-HMF. The lethal concentration of GDPs that killed 50% of neutrophils (LC50) was compared with the concentration of GDPs found in the infusion fluids (Table 1). The LC50 value for the most reactive GDPs, 3,4-DGE and formaldehyde, was 47 and 44 μM, respectively. The majority of the investigated fluids contained higher concentrations of 3,4-DGE than 47 μM (Table 1). The LC50 value for the less reactive molecules 3-DG and 5-HMF was higher, 1,374 μM and 2,463 μM, respectively.
GDPs diminished the inflammatory response
To investigate the impact of GDPs on neutrophil function, we measured the nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-mediated secretion of reactive oxygen species (ROS) from infected cells (see Supplementary Fig. 4). Formaldehyde and 3,4-DGE significantly inhibited neutrophil microbial killing, by 43% and 56%, respectively (P < 0.001), while 3-DG and 5-HMF suppressed neutrophil microbial killing by 35% and 23% (P < 0.01). Neutrophil capacity to kill bacteria was further inhibited with fluid 3 (57%) and to a lesser extent with fluid 2 (10%). The sterile filtered control fluids were not found to reduce neutrophil ROS secretion.
All investigated glucose-containing infusion fluids contained high amounts of GDPs. Moreover, increased concentrations of GDPs were found in blood circulation of critically ill patients receiving standard postoperative fluid therapy. The amount of 3-DG in the serum of a healthy human is approximately 0.2 μM , and increases twofold with disease such as diabetes and threefold in uremia . Before infusion, all patients had normal levels of 3-DG, but the concentration increased eightfold shortly after infusion of glucose-containing infusion fluids and did not reach the background level even after 9 h. In contrast, serum and urinary 3-DG levels were low in the control patients who received buffered saline. This finding suggests that the increased 3-DG found in serum of patients receiving the standard postoperative fluid therapy with glucose originated from the high amounts of GDPs found in these fluids. We did not succeed in measuring the amount of the more reactive GDPs, since these molecules bind to proteins immediately after infusion and their unbound concentrations were thus below the detection limit . Therefore, none of the infused 3,4-DGE was detected in serum or in urine at the end of the study. Of the infused 3-DG in the glucose-containing infusion fluids, we found 2% unbound in serum and only 9.6% in urine at the end of our study. This means that 88% of the infused 3-DG is gone, possibly bound to serum proteins, giving rise to advanced glycation end products (AGEs) . The serum amount of 5-HMF doubled during the experiment, and urinary secretion of this inert molecule increased fourfold. One explanation for the increased 5-HMF concentration might be that 3-DG is converted to 5-HMF through equilibrium with the reactive 3,4-DGE [17, 18]. This could explain the increased concentration of 5-HMF found in urine, but it also demonstrates that 3-DG is a reservoir for newly formed highly reactive 3,4-DGE.
There was a linear correlation between the amount of infused 3-DG and the increased formation of CML, a marker of AGE formation. Serum CML levels were low in the control patients receiving buffered saline in this study. The results are in good agreement with a recent publication by Humpert et al.  showing that human serum albumin (HSA) preparations for intravenous use contain high levels of CML. Furthermore, they found that the infusion of these CML-containing HSA preparations induced inflammation and caused increased mortality in experimental peritonitis. Furthermore, patients with renal failure accumulate 3-DG in serum due to impaired glucose metabolism and impaired renal clearance. In two recent studies, hemodialysis (HD) was shown to effectively remove AGEs and 3-DG, while an increase of this molecule was observed after PD treatment [28, 29]. This discrepancy was found to originate from the fluids used in the two modes of dialysis, i.e., PD fluids contain high amounts of GDPs while the HD fluids were low in GDPs. Levels of AGEs are also known to be significantly elevated in postoperative complications after major operations such as surgical coronary artery revascularization and renal transplantation [30, 31]. The patients in our study went through a broad range of fairly uncomplicated operations, but we found a restricted dissemination in serum CML concentration. This indicates that the increase is related to the infusion fluids rather than to the surgery.
Infusion fluids containing high levels of GDPs may have systemic effects resulting from local cytotoxic activity on blood vessels and blood cells, but also an indirect effect due to enhanced systemic AGE formation. Increased 3-DG has been shown to lead to a threefold increase in kidney lesions after 3 days in a rat model . Among the patients in our study, we observed an eightfold increase in serum 3-DG after receiving 1.7 l of GDP-containing infusion fluid. In more critically ill patients, it is not unusual for patients to receive 4 l of infusion fluids every day, for 2 days or longer. The more reactive GDP, formaldehyde, is connected to various forms of cancer in humans , and Zwart et al.  showed that rats exposed to 10 μM formaldehyde experienced a significant increase of cell turnover. However, the best way to state the possible importance of GDPs in clinical practice is perhaps to demonstrate what happens when they are blocked. It is well known that reactive carbonyl compounds play an important role in the development of diabetic complications. A promising drug candidate for treatment of diabetic nephropathy is pyroxidamine, which is currently on the Food and Drug Administration (FDA) “fast track” for phase III clinical trials . Pyroxidamine is a scavenger for reactive carbonyl compounds such as 3-DG , and has been shown in a phase II clinical study to ameliorate nephropathy [37, 38], enhance whole-body insulin sensitivity , increase creatinine clearance, and reduce inflammation and formation of AGEs. These data suggest that sterilization improvement leading to GDP removal from infusion fluids could be beneficial for insulin sensitivity and renal protection in intensive care patients.
Severely hyperglycemic patients typically suffer from complications such as infections and decreased wound healing. Recent studies have revealed that GDPs interfere with carbohydrate metabolism . In this study, we found that the most reactive GDP, 3,4-DGE, was present at concentrations that could decrease neutrophil viability and affect cell function. Furthermore, neutrophil exposure to GDPs or the infusion fluids significantly inhibited secretion of cytokines involved in inflammatory conditions. These findings show that normal postoperative fluid treatment involves infusion of potentially dangerous fluids into patients. These observations are in good agreement with a study by Catalan et al.  showing that GDPs cause neutrophil apoptosis. We analyzed the oxidative burst in human neutrophils treated with GDPs or infusion fluids as a functional measurement of neutrophil function upon bacterial infection. We found that the oxidative burst was greatly inhibited both by GDPs and by the diluted infusion fluids. The ability of GDPs to impair microbial killing could thus contribute to the infection susceptibility and decreased wound healing that are observed in hyperglycemic patients.
The results of this study indicate that normal postoperative fluid treatment involves infusion of dangerously high concentrations of GDPs. New manufacturing techniques have reduced the amounts of GDPs in medical fluids, making these more biocompatible [17, 18]. It seems evident that the same approach in manufacturing should be introduced for fluids for intravenous use.
Supported, in part, by a Research Scientist Grant from the Swedish Medical Research Council (2005-7364 and 2008-5135). The employees of Gambro Lundia AB listed as authors participated with other authors in the study design, but did not participate in the collection, analysis, or interpretation of the data. The authors have not disclosed any potential conflicts of interest. We thank Dr. H. Janson for scientific support and Robert George Dewsnap for linguistic revision. We thank also Mrs. E. Svensson and Mrs. G. Forsbäck for excellent technical assistance and Mrs. A. Johansson for help with clinical material.
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.